Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rani Therapeutics Holdings, Inc. (RANI)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
7.99-0.20 (-2.44%)
At close: 04:00PM EST
7.99 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement

Rani Therapeutics Holdings, Inc.

2051 Ringwood Avenue
San Jose, CA 95131
United States
408 457 3700
https://www.ranitherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees114

Key Executives

NameTitlePayExercisedYear Born
Mr. Mir A. ImranExec. Chairman33.33kN/A1956
Mr. Talat ImranCEO & Director1.07MN/A1981
Mr. Svai S. SanfordChief Financial Officer675.74kN/A1970
Dr. Mir HashimChief Scientific Officer696.92kN/A1960
Mr. Eric GroenGen. CounselN/AN/AN/A
Ms. Bella VazquezVP of HRN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Corporate Governance

Rani Therapeutics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement